Eiger announces FDA Fast Track designation granted for Pegylated Interferon Lambda
Eiger BioPharmaceuticals announced the FDA has granted Fast Track designation for pegylated interferon lambda 1a as a potential treatment for chronic hepatitis delta virus infection. Eiger licensed worldwide rights to Lambda from Bristol-Myers Squibb in April 2016. July 27, 2017